T1	Disease	65 91	anaplastic lymphoma kinase
T2	Chemical	62 122	an anaplastic lymphoma kinase inhibitor ( crizotinib ) based
T3	Pharmacodynamic_phenotype	148 164	response rate in
T4	Disease	188 219	small cell lung cancer patients
T5	Disease	226 239	tumors harbor
T6	Genomic_variation	245 269	4 / ALK translocations .
R1	influences	Arg1:T1	Arg2:T2
R2	treats	Arg1:T1	Arg2:T4
R3	treats	Arg1:T1	Arg2:T5
R4	isAssociatedWith	Arg1:T1	Arg2:T6
R5	decreases	Arg1:T2	Arg2:T1
R6	treats	Arg1:T2	Arg2:T4
R7	treats	Arg1:T2	Arg2:T5
R8	isAssociatedWith	Arg1:T2	Arg2:T6
R9	isAssociatedWith	Arg1:T3	Arg2:T1
R10	isAssociatedWith	Arg1:T3	Arg2:T2
R11	treats	Arg1:T3	Arg2:T4
R12	isAssociatedWith	Arg1:T3	Arg2:T5
R13	isAssociatedWith	Arg1:T3	Arg2:T6
R14	isAssociatedWith	Arg1:T4	Arg2:T3
R15	isAssociatedWith	Arg1:T4	Arg2:T5
R16	isAssociatedWith	Arg1:T4	Arg2:T6
R17	isAssociatedWith	Arg1:T5	Arg2:T1
R18	influences	Arg1:T5	Arg2:T2
R19	isAssociatedWith	Arg1:T5	Arg2:T3
R20	isAssociatedWith	Arg1:T5	Arg2:T4
R21	isAssociatedWith	Arg1:T5	Arg2:T6
R22	influences	Arg1:T6	Arg2:T1
R23	influences	Arg1:T6	Arg2:T2
R24	influences	Arg1:T6	Arg2:T3
R25	isAssociatedWith	Arg1:T6	Arg2:T4
R26	isAssociatedWith	Arg1:T6	Arg2:T5
